ARTICLE | Clinical News

Grifols' AMBAR approach slows disease progression in moderate Alzheimer’s

October 29, 2018 11:09 PM UTC

Grifols S.A. (Madrid:GRF; NASDAQ:GRFS) reported Phase IIb/III data on its AMBAR approach to treat Alzheimer’s disease demonstrating evidence of mechanism and improvements in clinical outcomes.

AMBAR, which stands for Alzheimer Management by Albumin Replacement, was designed to evaluate whether Alzheimer’s progression could be slowed through periodic plasma exchange, in which plasma is extracted and replaced with albumin. The approach is based on the hypothesis that most β-amyloid is bound to albumin and circulates in plasma. The company said that undergoing periodic plasma exchange could disrupt the dynamic equilibrium between the CSF and plasma and move β-amyloid from the brain into the plasma where some of the protein would be captured by the new albumin, thereby reducing the buildup of β-amyloid in the brain before it can cause neuronal damage...

BCIQ Company Profiles

Grifols S.A.